ECOR enters its Q1 2026 results — scheduled for May 6 — with a stock that has run hard while short sellers look far from alarmed.
The week's most interesting tension is the gap between price and positioning. The stock jumped 14% over the past five sessions to close at $6.99, extending a 56% gain year-to-date. Yet short sellers have barely reacted. This is a rally that the bear camp is watching, not chasing.
Short interest at 4.4% of the free float is not an extreme reading for a small-cap medtech. It has crept up roughly 12% over the past month — from around 315,000 shares to 351,656 — but the move looks more like passive drift than a conviction build. Days to cover came in at 3.5 per the most recent FINRA fortnightly report, unremarkable for a name with this float. The borrow itself remains cheap and accessible: cost to borrow is running at 2.25% annualised, up about 29% over the past month in percentage terms but still at a level that represents no real friction for would-be shorts. Availability, while tighter than it was in early spring — borrow usage has climbed from roughly 40% in late March to 50% now — is still well below half-utilised, a long way from the 78% peak seen over the past year. The lending market, in short, shows no squeeze pressure.
The ORTEX short score at 64.5 sits in the moderate zone. It has edged up from 63.3 at the start of last week, a steady rather than sudden climb. The short-score rank lands in just the 9th percentile of its peer group — meaning most health-care equipment names carry more short-side conviction than ECOR does. The days-to-cover rank is equally low at the 9th percentile. The message from positioning is that this is not a heavily shorted name trying to run; it is a lightly-to-moderately shorted small-cap with a rallying stock and shorts who have not yet flinched.
The Street remains unanimously bullish on paper. Every available analyst rating is a Buy, and the consensus mean price target of $19.80 implies more than 180% upside from the current price. However, the most recent target change on record — HC Wainwright cutting from $25 to $18 in late January 2026 — points to analysts pulling back expectations even as they hold their ratings. The target history tells a story of optimism tempered over time. Given the $6.99 close, even the reduced $18 target implies the Street sees meaningful undervaluation; at the same time, the spread between price and target is wide enough to warrant caution about stale assumptions. Quarterly fundamentals show estimated revenue of $9 million and a net loss of around $5.5 million — a business still burning cash and dependent on growth execution for its valuation to make sense.
The insider register offers a small but consistent signal. The company's founder and director Thomas Errico has made multiple open-market purchases over the past year, including 15,000 shares in August 2025 and 6,000 shares in March 2025. The former CEO Daniel Goldberger — who also held the CEO role through early 2026 before the designation shifted to "Former CEO" — made a small open-market purchase in December 2025 at $4.84. He then sold 16,072 shares in April 2026 at $6.02, a modest disposal that likely reflects routine activity rather than a directional call. The net 90-day insider position is marginally negative in shares but trivial in value. Ownership remains concentrated: the top four holders together control roughly 26% of shares outstanding, suggesting limited free float and the potential for outsized moves on volume.
Peer CERS gained 31% over the same week, an unusually strong move for a correlated name. STE edged up 0.3% on the day but fell 3% on the week — a reminder that broader health-care equipment is not uniformly in rally mode.
The Q1 results due today are the immediate focal point. The last earnings-day reaction on record was a 9.4% drop on March 19, with the stock extending the move to minus 12.8% over the following five days. Whether the current 14% weekly run leaves the stock exposed to a similar fade, or whether a clean Q1 print resets the narrative for the rest of the year, is the question the market will answer before the week is out.
See the live data behind this article on ORTEX.
Open ECOR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
